NZ591146A - Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills - Google Patents

Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills

Info

Publication number
NZ591146A
NZ591146A NZ591146A NZ59114609A NZ591146A NZ 591146 A NZ591146 A NZ 591146A NZ 591146 A NZ591146 A NZ 591146A NZ 59114609 A NZ59114609 A NZ 59114609A NZ 591146 A NZ591146 A NZ 591146A
Authority
NZ
New Zealand
Prior art keywords
aggregates
stem cell
mesenchymal stem
micomills
composition
Prior art date
Application number
NZ591146A
Other languages
English (en)
Inventor
Alla Danilkovich
Robert E Newman
Samson Tom
Christopher Ton
Zhanling Wang
Randal Young
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Priority to NZ602248A priority Critical patent/NZ602248A/en
Publication of NZ591146A publication Critical patent/NZ591146A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ591146A 2008-08-14 2009-08-14 Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills NZ591146A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14
PCT/US2009/053891 WO2010019886A1 (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Publications (1)

Publication Number Publication Date
NZ591146A true NZ591146A (en) 2012-10-26

Family

ID=41669330

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ591146A NZ591146A (en) 2008-08-14 2009-08-14 Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Country Status (14)

Country Link
US (6) US8637004B2 (enExample)
EP (3) EP2318519B1 (enExample)
JP (7) JP6025329B2 (enExample)
AR (2) AR073069A1 (enExample)
AU (1) AU2009281809B2 (enExample)
BR (1) BRPI0917993B8 (enExample)
CA (1) CA2733985C (enExample)
DK (1) DK2318519T3 (enExample)
ES (1) ES2608974T3 (enExample)
IL (1) IL211214A0 (enExample)
MX (2) MX362512B (enExample)
NZ (2) NZ591146A (enExample)
WO (1) WO2010019886A1 (enExample)
ZA (1) ZA201101858B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2007087139A2 (en) 2006-01-13 2007-08-02 Osiris Therapeutics, Inc. MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR
CA2733985C (en) 2008-08-14 2016-07-12 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
EP3539380A3 (en) 2008-08-20 2019-12-18 Celularity, Inc. Improved cell composition and methods of making the same
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10449283B2 (en) * 2016-04-29 2019-10-22 Fenwal, Inc. System and method for selecting and culturing cells
US10251990B2 (en) 2016-04-29 2019-04-09 Fenwal, Inc. System and method for processing, incubating, and/or selecting biological cells
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3338823B1 (en) 2016-12-21 2021-06-16 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
KR20200088445A (ko) 2017-11-22 2020-07-22 메조블라스트 인터내셔널 에스에이알엘 세포 조성물 및 치료 방법 i
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
WO2020084135A1 (en) * 2018-10-26 2020-04-30 Stemselect Method and apparatus for mesenchymal stem cells isolation and purification
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
CA3137570A1 (en) * 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115478046A (zh) * 2022-09-30 2022-12-16 浙江泉生生物科技有限公司 一种降低血清培养体系中细胞制剂bsa残留量的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
JP2881305B2 (ja) * 1986-08-11 1999-04-12 バクスター、インターナショナル、インコーポレイテッド 血球洗浄システムおよび方法
US5536475A (en) * 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5234608A (en) * 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
JPH10505250A (ja) * 1994-06-06 1998-05-26 ケース ウエスターン リザーブ ユニバーシティ 組織再生のためのバイオマトリックス
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
AU731468B2 (en) * 1996-04-19 2001-03-29 Mesoblast International Sarl Regeneration and augmentation of bone using mesenchymal stem cells
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
DK1007631T4 (da) * 1997-07-14 2009-04-27 Osiris Therapeutics Inc Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
JP4740452B2 (ja) 1998-03-18 2011-08-03 オシリス セラピューティクス，インコーポレイテッド 移植で免疫応答の予防と処置のための間葉幹細胞を利用する方法、組成物およびその使用法
CA2328425A1 (en) * 1998-05-22 1999-12-02 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
FR2787463B1 (fr) 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US8105580B2 (en) * 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US20050008626A1 (en) 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
EP2308963A3 (en) * 2001-12-07 2011-09-21 Cytori Therapeutics, Inc. System for processing lipoaspirate cells
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ITTO20020311A1 (it) * 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
AU2004260937B2 (en) 2003-06-25 2010-05-13 Macropore Biosurgery Inc. Systems and methods for separating and concentrating regenerative cells from tissue
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
WO2006135854A2 (en) * 2005-06-10 2006-12-21 Board Of Regents, The University Of Texas System Antiseptic compositions
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
WO2007089798A2 (en) 2006-01-30 2007-08-09 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
EP2021035B1 (en) 2006-05-19 2020-08-05 Versitech Limited Cell-matrix microspheres, methods for preparation and applications
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
CA2913024A1 (en) * 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
KR20090086260A (ko) 2006-12-07 2009-08-11 테바 파마슈티컬 인더스트리즈 리미티드 미손상 골수 또는 미손상 제대 조직으로부터 조직 전구체 세포 및 성숙 조직 세포를 형성 및 증식시키는 방법
CN101210232B (zh) * 2006-12-28 2012-07-18 天津昂赛细胞基因工程有限公司 一种间充质干细胞保存液
EP2191835A4 (en) 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
JP5394932B2 (ja) 2007-11-02 2014-01-22 日本ケミカルリサーチ株式会社 ヒト間葉系幹細胞含有医薬組成物
CA2733985C (en) 2008-08-14 2016-07-12 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US8048976B2 (en) 2008-09-04 2011-11-01 Amyris, Inc. Polyfarnesenes
US10476476B2 (en) 2016-12-15 2019-11-12 Murata Manufacturing Co., Ltd. MEMS resonator with suppressed spurious modes

Also Published As

Publication number Publication date
EP4477742A2 (en) 2024-12-18
AU2009281809A1 (en) 2010-02-18
EP2318519A4 (en) 2013-07-24
WO2010019886A1 (en) 2010-02-18
JP2015071610A (ja) 2015-04-16
JP2025122125A (ja) 2025-08-20
IL211214A0 (en) 2011-04-28
EP2318519B1 (en) 2016-10-05
CA2733985A1 (en) 2010-02-18
US20100068191A1 (en) 2010-03-18
NZ602248A (en) 2014-03-28
JP2017081972A (ja) 2017-05-18
ZA201101858B (en) 2011-11-30
US20230089901A1 (en) 2023-03-23
JP2023052211A (ja) 2023-04-11
AU2009281809B2 (en) 2015-09-17
BRPI0917993B8 (pt) 2021-05-25
MX2011001730A (es) 2011-03-24
ES2608974T3 (es) 2017-04-17
JP2012500214A (ja) 2012-01-05
JP2020120671A (ja) 2020-08-13
JP6025329B2 (ja) 2016-11-16
US20200197444A1 (en) 2020-06-25
US20140105872A1 (en) 2014-04-17
JP2018109052A (ja) 2018-07-12
CA2733985C (en) 2016-07-12
BRPI0917993A2 (pt) 2017-10-10
MX362512B (es) 2019-01-22
US8637004B2 (en) 2014-01-28
DK2318519T3 (en) 2017-01-16
BRPI0917993B1 (pt) 2020-12-29
AR073069A1 (es) 2010-10-13
US20250312379A1 (en) 2025-10-09
EP4477742A3 (en) 2025-02-26
US20180008642A1 (en) 2018-01-11
EP2318519A1 (en) 2011-05-11
AR123811A2 (es) 2023-01-18
EP3124601A1 (en) 2017-02-01
JP7580202B2 (ja) 2024-11-11

Similar Documents

Publication Publication Date Title
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP4483952A3 (en) Compositions suitable for treating collagen-mediated diseases
IN2012DN01233A (enExample)
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
MX360598B (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12016500746B1 (en) A novel formulation of meloxicam
PH12013501437A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
MX2010003914A (es) Nuevas composiciones a base de taxoides.
PH12012502253A1 (en) Oral care compositions and methods
TN2010000243A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 AUG 2016 BY DENNEMEYER + CO

Effective date: 20130725

ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 892120, FB RICE, C/- DLA PHILLIPS FOX, PO BOX 160, SHORTLAND STREET, AUCKLAND 1140, NZ; THE CONTACT HAS BEEN CORRECTED TO 892120, FB RICE, C/- DLA PHILLIPS FOX, PO BOX 160, SHORTLAND STREET, AUCKLAND 1140, NZ

Effective date: 20140715

ASS Change of ownership

Owner name: MESOBLAST INTERNATIONAL SARL C/O ACCOUNTING AN, CH

Effective date: 20150416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2017 BY CPA GLOBAL

Effective date: 20160729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2018 BY CPA GLOBAL

Effective date: 20170629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2019 BY CPA GLOBAL

Effective date: 20180628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2020 BY CPA GLOBAL

Effective date: 20190628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2021 BY CPA GLOBAL

Effective date: 20200702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2022 BY CPA GLOBAL

Effective date: 20210701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2023 BY CPA GLOBAL

Effective date: 20220630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2024 BY CPA GLOBAL

Effective date: 20230701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240627

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250703